Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031

Nov 2022| TBR1173D| TBRC (Publisher)

Report Highlights

Including: 1) By Product: Adalimumab Biosimilars; Infliximab Biosimilars; Cipleumab
2) By Application: Crohn’s Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Other Applications
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Biogen; Novartis (Sandoz); Pfizer; Amgen; Celltrion

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global adalimumab, infliximab and etanercept biosimilars market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Description:
Where is the largest and fastest growing market for adalimumab, infliximab and etanercept biosimilars? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The adalimumab, infliximab and etanercept biosimilars market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider adalimumab, infliximab and etanercept biosimilars market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about adalimumab, infliximab and etanercept biosimilars market.
  • Key Trends - Highlights the major trends shaping the global adalimumab, infliximab and etanercept biosimilars market. This section also highlights likely future developments in the market.
  • Global Market Size and Growth - Global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional Analysis - Historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values and growth and market share comparison by region.
  • Market Segmentation - Contains the market values (2016-2031) and analysis for for segment by product, by application, and by distribution channel in the market.
  • Regional Market Size and Growth - Regional market size (2021), historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Pipeline Analysis - Briefs on the pipeline analysis of adalimumab, infliximab and etanercept biosimilars from the major players in the market.
  • Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations - Includes recommendations for adalimumab, infliximab and etanercept biosimilars providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Frequently Asked Questions (FAQs)

Scope

Markets Covered:

  • By Product: Adalimumab Biosimilars; Infliximab Biosimilars; Cipleumab
  • By Application: Crohn’s Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Other Applications
  • By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Companies Mentioned: Biogen; Novartis (Sandoz); Pfizer; Amgen; Celltrion

Countries: Australia; China; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; adalimumab, infliximab and etanercept biosimilars indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

  • Table 1 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 2 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 3 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 4 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 5 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 6 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 7 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 8 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 9 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 10 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 11 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 12 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 13 : Asia-Pacific Population By Age Group, By Country, 2016-2026, Thousands
  • Table 14 : Asia-Pacific GDP Per Capita, By Country, 2016-2021, $
  • Table 15 : Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 16 : Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 17 : Asia-Pacific, Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 18 : Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 19 : Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 20 : Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 21 : Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 22 : China Population By Age Group, 2016-2026, Thousands
  • Table 23 : China GDP Per Capita, 2016-2021, $
  • Table 24 : China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 25 : China Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 26 : China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 27 : China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 28 : China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 29 : China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 30 : India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 31 : India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 32 : India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 33 : India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 34 : Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 35 : Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 36 : Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 37 : Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 38 : Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 39 : Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 40 : Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 41 : Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 42 : Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 43 : Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 44 : Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 45 : Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 46 : South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 47 : South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 48 : South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 49 : South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 50 : Western Europe Population By Age Group, By Country, 2016-2026, Thousands
  • Table 51 : Western Europe GDP Per Capita, By Country, 2016-2021, $
  • Table 52 : Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 53 : Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 54 : Western Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 55 : Western Smart Europe Washing Machines Market, Historic, 2016 – 2021, $ Million
  • Table 56 : Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 57 : Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 58 : Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 59 : UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 60 : UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 61 : UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 62 : UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 63 : Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 64 : Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 65 : Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 66 : Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 67 : France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 68 : France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 69 : France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 70 : France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 71 : Eastern Europe Population By Age Group, By Country, 2016-2026, Thousands
  • Table 72 : Eastern Europe GDP Per Capita, By Country, 2016-2021, $
  • Table 73 : Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 74 : Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 75 : Eastern Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 76 : Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 77 : Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 78 : Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 79 : Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 80 : Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 81 : Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 82 : Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 83 : Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 84 : North America Population By Age Group, By Country, 2016-2026, Thousands
  • Table 85 : North America GDP Per Capita, By Country, 2016-2021, $
  • Table 86 : North America Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 87 : North America Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 88 : North America Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 89 : North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 90 : North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 91 : North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 92 : North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 93 : USA Population By Age Group, 2016-2026, Thousands
  • Table 94 : USA GDP Per Capita, 2016-2021, $
  • Table 95 : USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 96 : USA Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 97 : USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 98 : USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 99 : USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 100 : USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 101 : South America Population By Age Group, By Country, 2016-2026, Thousands
  • Table 102 : South America GDP Per Capita, By Country, 2016-2021, $
  • Table 103 : South America Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 104 : South America Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 105 : South America Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 106 : South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 107 : South America Washing Machines Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 108 : South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 109 : South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 110 : Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 111 : Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 112 : Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 113 : Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 114 : Middle East Population By Age Group, By Country, 2016-2026, Thousands
  • Table 115 : Middle East GDP Per Capita, By Country, 2016-2021, $
  • Table 116 : Middle East Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 117 : Middle East Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 118 : Middle East Healthcare Services Market Size, 2016-2026, $ Billion
  • Table 119 : Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 120 : Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 121 : Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 122 : Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 123 : Africa Population By Age Group, By Country, 2016-2026, Thousands
  • Table 124 : Africa GDP Per Capita, By Country, 2016-2021, $
  • Table 125 : Africa Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 126 : Africa Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 127 : Africa Healthcare Services Market Size, 2016-2026, $ Billion
  • Table 128 : Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 129 : Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 130 : Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 131 : Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 132 : Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)
  • Table 133 : Biogen – Financial Performance, 2017– 2021, $ Billion
  • Table 134 : Novartis – Financial Performance, 2017– 2021, $ Billion
  • Table 135 : Pfizer – Financial Performance, 2017– 2021, $ Billion
  • Table 136 : Amgen – Financial Performance, 2017– 2021, $ Billion
  • Table 137 : Celltrion – Financial Performance, 2017– 2021, $ Billion
  • Table 138 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), 2021 – 2026, By Country
  • Table 139 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Product, 2021 – 2026
  • Table 140 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2021 – 2026
  • Table 141 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Distribution Channel, 2021 – 2026
  • Table 142 : Adalimumab, Infliximab and Etanercept Biosimilars Market Data Sources
  • Figure 1 : Geographic Regions Covered
  • Figure 2 : Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Product
  • Figure 3 : Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Application
  • Figure 4 : Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Distribution Channel
  • Figure 5 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 6 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 7 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 8 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 9 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 10 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 11 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 12 : Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 13 : Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 14 : Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 15 : China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 16 : China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 17 : China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 18 : India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 19 : India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 20 : India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 21 : Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 22 : Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 23 : Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 24 : Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 25 : Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 26 : Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 27 : Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 28 : Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 29 : Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 30 : South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 31 : South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 32 : South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 33 : Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 34 : Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 35 : Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 36 : UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 37 : UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 38 : UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 39 : Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 40 : Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 41 : Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 42 : France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 43 : France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 44 : France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 45 : Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 46 : Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 47 : Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 48 : Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 49 : Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 50 : Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 51 : North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 52 : North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 53 : North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 54 : USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 55 : USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 56 : USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 57 : South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 58 : South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 59 : South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 60 : Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 61 : Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 62 : Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 63 : Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 64 : Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 65 : Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 66 : Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 67 : Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 68 : Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 69 : Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)
  • Figure 70 : Biogen – Financial Performance, $ Billion
  • Figure 71 : Novartis – Financial Performance, 2017– 2021, $ Billion
  • Figure 72 : Pfizer – Financial Performance, 2017– 2021, $ Billion
  • Figure 73 : Amgen – Financial Performance, 2017– 2021, $ Billion
  • Figure 74 : Celltrion – Financial Performance, 2017– 2021, $ Billion

The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Similar Reports from TBRC (Publisher)

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2022

  • Date - Mar 2022
  • Code - TBR1173C

Including: 1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others); Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)
2) By Application: Crohn’S Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen; Boehringer Ingelheim; ...

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030

  • Date - Sep 2021
  • Code - TBR1173B

Including: 1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others); Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)
2) By Application: Crohn’S Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen

Adalimumab, Infliximab ...

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change

  • Date - Dec 2020
  • Code - TBR1173A

Including: 1) By Product: Adalimumab biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, others); Infliximab biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)

2) By Application: Crohn’s disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Ankylosing spondylitis; Plaque psoriasis; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Covering: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen

Adalimumab, Infliximab and Etanercept ...

The Business Research Company
Price: $5000

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.